Summary
17.23 0.34(2.01%)05/15/2024
Celcuity Inc (CELC)
Celcuity Inc (CELC)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
0.31 | 10.61 | -9.69 | 12.60 | 72.85 | 88.50 | -16.51 | -9.23 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 17.70 | |
Open | 17.85 | |
High | 17.85 | |
Low | 17.49 | |
Volume | 29,818 | |
Change | 0.06 | |
Change % | 0.31 | |
Avg Volume (20 Days) | 203,775 | |
Volume/Avg Volume (20 Days) Ratio | 0.15 | |
52 Week Range | 8.39 - 22.19 | |
Price vs 52 Week High | -20.23% | |
Price vs 52 Week Low | 110.97% | |
Range | -0.84 | |
Gap Up/Down | -0.12 |
Fundamentals | ||
Market Capitalization (Mln) | 525 | |
EBIDTA | -7,450,598 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 43.75 | |
Book Value | 4.9960 | |
Earnings Per Share | -2.0790 | |
EPS Estimate Current Quarter | -0.3100 | |
EPS Estimate Next Quarter | -0.4000 | |
EPS Estimate Current Year | -2.1200 | |
EPS Estimate Next Year | -2.6100 | |
Diluted EPS (TTM) | -2.0790 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 0.0000 | |
Return on asset (TTM) | -0.2879 | |
Return on equity (TTM) | -0.5758 | |
Revenue TTM | 0 | |
Revenue per share TTM | 0.0000 | |
Quarterly Revenue Growth (YOY) | 0.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 0 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 2.6703 | |
Revenue Enterprise Value | 0.0000 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 14,918,900 | |
Shares Float | 9,747,270 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 30.19 | |
Institutions (%) | 39.78 |
05/15 19:43 EST - seekingalpha.com
Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Brad Canino - Stifel Gil Blum - Needham & Company Operator Good afternoon, ladies and gentlemen. And welcome the Celcuity First Quarter 2024 Financial Results Conference call.
Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Brad Canino - Stifel Gil Blum - Needham & Company Operator Good afternoon, ladies and gentlemen. And welcome the Celcuity First Quarter 2024 Financial Results Conference call.
05/15 16:01 EST - globenewswire.com
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the first quarter ended March 31, 2024 and other recent business developments.
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the first quarter ended March 31, 2024 and other recent business developments.
05/08 07:05 EST - globenewswire.com
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
04/04 07:05 EST - globenewswire.com
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
03/27 18:40 EST - seekingalpha.com
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript
03/27 16:01 EST - globenewswire.com
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MINNEAPOLIS, March 27, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2023 and other recent business developments.
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MINNEAPOLIS, March 27, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2023 and other recent business developments.
03/21 12:21 EST - zacks.com
Why Celcuity (CELC) Might Surprise This Earnings Season
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Celcuity (CELC) Might Surprise This Earnings Season
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
03/20 07:05 EST - globenewswire.com
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
03/06 07:05 EST - globenewswire.com
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 to be held in Miami on March 11-13, 2024.
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 to be held in Miami on March 11-13, 2024.
02/28 07:05 EST - globenewswire.com
Celcuity to Participate in Cowen's 44th Annual Health Care Conference
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in Cowen's 44th Annual Health Care Conference to be held in Boston on March 4-6, 2024.
Celcuity to Participate in Cowen's 44th Annual Health Care Conference
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in Cowen's 44th Annual Health Care Conference to be held in Boston on March 4-6, 2024.
02/20 07:05 EST - globenewswire.com
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology.
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology.
12/06 08:30 EST - globenewswire.com
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS).
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS).
12/01 11:02 EST - globenewswire.com
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023.
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium (SABCS) is being held virtually and in-person from December 5-9, 2023.
11/22 08:05 EST - globenewswire.com
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 6th Annual Evercore ISI HealthCONx Conference held in Miami.
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 6th Annual Evercore ISI HealthCONx Conference held in Miami.
11/13 12:41 EST - seekingalpha.com
Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript
Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript
Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript
Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript
11/13 07:05 EST - globenewswire.com
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial results for the third quarter ended September 30, 2023 and provided other recent corporate updates.
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today reported financial results for the third quarter ended September 30, 2023 and provided other recent corporate updates.
11/06 07:30 EST - globenewswire.com
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023. Management will host a webcast/teleconference the same day at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update.
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023. Management will host a webcast/teleconference the same day at 8:00 a.m. Eastern Time to discuss the results and provide a corporate update.
11/01 07:05 EST - GlobeNewsWire
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
10/18 09:15 EST - accesswire.com
Celcuity Inc. Announces $50 Million Private Placement
MINNEAPOLIS, MN / ACCESSWIRE / October 18, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50 million. In the private placement, an institutional investor has agreed to purchase pre-funded warrants to purchase shares of Celcuity's common stock at a price of $8.699 per warrant, each with an exercise price of $0.001 per share (for aggregate consideration equating to $8.70 per share).
Celcuity Inc. Announces $50 Million Private Placement
MINNEAPOLIS, MN / ACCESSWIRE / October 18, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50 million. In the private placement, an institutional investor has agreed to purchase pre-funded warrants to purchase shares of Celcuity's common stock at a price of $8.699 per warrant, each with an exercise price of $0.001 per share (for aggregate consideration equating to $8.70 per share).
09/21 16:43 EST - investorplace.com
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.